LY3305677 + LY3841136 + LY3549492

This is an investigational combination of three Eli Lilly-developed drugs—**LY3305677 (also known as IBI362, mazdutide)**, **LY3841136**, and **LY3549492**—being evaluated primarily for chronic weight management and obesity. - **LY3305677**: A once-weekly, subcutaneously injected dual agonist of the **glucagon-like peptide-1 (GLP-1) receptor** and **glucagon receptor**, advancing for obesity and type 2 diabetes[7][2]. - **LY3841136**: Reported in studies as a novel agent for chronic weight management, both as monotherapy and in combination with tirzepatide[1][5][9]. - **LY3549492**: Investigated as an oral therapy for chronic weight management in adults with obesity or overweight, under master protocols that also test other candidates[4][8]. All three drugs are investigated together (and in various combinations) under a master protocol for their cumulative weight loss effects and metabolic benefits in overweight or obese adults, with or without type 2 diabetes[9][16].

Other names

IBI362IBI-362IBI 362mazdutide